2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: A Versatile Immune-Stimulatory Actinium-225 Complex for Combination Radiotherapy and Antibody Recruiting Therapy

Ottawa, ON, Canada (UroToday.com) The central premise of this study is that by adding an immuno-recruiting molecule to the conventional radio-labeled antibody ligand, the radiation cytotoxic effect can be enhanced with the body’s immune system. For the study, tetrazine was used for the antibody end, DOTA as the chelating agent, and a 2,4-dinitrophenyl moiety on the recruiting end.

For the tumor studies, this ligand was linked to TCO functionalized bovine serum albumin (BSA) aggregates. The Ac225 or Lu177 labeled conjugate was injected directly into a 4T1 breast cancer model. There was a very high tumor uptake with the aggregates, justifying further studies.


Presented by: Ms. Stephanie Rathmann, McMaster University, Hamilton, Ontario, Canada 

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada